Featured Research

from universities, journals, and other organizations

Deactivating a single protein corrects sickle cell disease in mice

Date:
October 13, 2011
Source:
Children's Hospital Boston
Summary:
Flipping a single molecular switch can reverse illness in a model of sickle cell disease, according to a new study. When turned off, the switch, a protein called BCL11A, allows the body to manufacture red blood cells with an alternate form of hemoglobin unaffected by the mutation that causes the disease.

Flipping a single molecular switch can reverse illness in a model of sickle cell disease, according to a study by researchers at Children's Hospital Boston and Dana-Farber Cancer Institute. When turned off, the switch, a protein called BCL11A, allows the body to manufacture red blood cells with an alternate form of hemoglobin unaffected by the mutation that causes the disease.

The findings -- reported online by a research team led by Stuart Orkin, MD, of the Dana-Farber/Children's Hospital Cancer Center (DF/CHCC) in the journal Science on Oct. 13 -- provide strong evidence that BCL11A could be a powerful treatment target for a significant global health problem, one that affects between 75,000 and 100,000 people in the United States alone.

"This study provides the first proof of principle that BCL11A might serve as a target for treating sickle cell disease, and related blood disorders such as the thalassemias," said Orkin, associate chief of the division of hematology/oncology at Children's Hospital Boston and chair of pediatric oncology at Dana-Farber.

First described over 100 years ago, sickle cell disease (or sickle cell anemia) is an inherited blood disease caused by a single mutation in one of the components of hemoglobin, the oxygen-carrying protein in red blood cells. The mutation reduces the protein's ability to carry oxygen, and forces the cells to curve into a distinctive crescent or sickle shape, causing them to painfully accumulate and break apart in small blood vessels.

The disease can only be cured with a bone marrow or stem cell transplant, though difficulties in finding well-matched donors and the complications associated with transplantation rules this out as an option for most patients. A drug called hydroxurea can provide some relief, but its mechanism of action is unclear and its efficacy unpredictable from patient to patient.

Our bodies can actually manufacture two forms of hemoglobin: the adult form susceptible to the sickle cell mutation, and a fetal form that is largely produced during development and for a short time after birth. Affected children first experience sickle cell symptoms around the time that our bodies switch from producing red blood cells with fetal hemoglobin to those with adult hemoglobin (approximately 3-6 months of age).

BCL11A first drew serious attention in genome-wide association studies of sickle cell disease patients. Shortly after the genomic data came to light, Orkin, who is also a Howard Hughes Medical Institute investigator and the David G. Nathan Professor of Pediatrics at Harvard Medical School, and his colleagues showed that by genetically knocking out BCL11A they could activate fetal hemoglobin and silence mutated adult hemoglobin in cultured normal human red cell progenitors.

"The red blood cell lineage performs a balancing act when it comes to manufacturing hemoglobin," Orkin explained. "Increasing the production of one form reduces production of the other."

In the current study, Orkin's team set out to assess the impact of removing BCL11A from the red blood cell lineage in the adult. Using two different mouse models of human sickle cell disease as a means of cross-validation, they engineered a system whereby they could selectively turn the protein off just in the immature progenitor cells that give rise to red blood cells.

The results in these mice were striking. Relieved of BCL11A's influence, the mice in both models started producing red blood cells that showed no evidence of sickling, with no adverse impact on the level of cell production. Eighty-five percent of the red blood cells in the mice carried fetal hemoglobin, and on average, 30 percent of the hemoglobin contained within these cells was of the fetal type. The mice also showed great improvement in a number of physiologic and clinical features.

"We knew from previous clinical studies that the body needs to produce cells containing only 15 to 20 percent fetal hemoglobin to reverse disease," Orkin said, "With these results we know now we have a target that, if we can develop ways to inactivate or silence it clinically, could be very beneficial to people with sickle cell."

He and his colleague are already pursuing several lines of investigation aimed at broadening their understanding of BCL11A and translating their mouse findings into potential treatments. "We want to better understand the network of genes and proteins that interact with BCL11A, to see if any of them might also stand out as targets," he said. "We also are screening the protein against libraries of chemicals in the hope of identifying compounds that interfere with it, and think it may also hold promise as a target for genetic therapies."

The study was supported by the National Heart, Lung, and Blood Institute; the National Cancer Institute; the National Institute of Diabetes and Digestive and Kidney Diseases, the Howard Hughes Medical Institute, and the Marie Betzner Morrow Endowment.


Story Source:

The above story is based on materials provided by Children's Hospital Boston. Note: Materials may be edited for content and length.


Cite This Page:

Children's Hospital Boston. "Deactivating a single protein corrects sickle cell disease in mice." ScienceDaily. ScienceDaily, 13 October 2011. <www.sciencedaily.com/releases/2011/10/111013141818.htm>.
Children's Hospital Boston. (2011, October 13). Deactivating a single protein corrects sickle cell disease in mice. ScienceDaily. Retrieved July 30, 2014 from www.sciencedaily.com/releases/2011/10/111013141818.htm
Children's Hospital Boston. "Deactivating a single protein corrects sickle cell disease in mice." ScienceDaily. www.sciencedaily.com/releases/2011/10/111013141818.htm (accessed July 30, 2014).

Share This




More Health & Medicine News

Wednesday, July 30, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Generics Eat Into Pfizer's Sales

Generics Eat Into Pfizer's Sales

Reuters - Business Video Online (July 29, 2014) Pfizer, the world's largest drug maker, cut full-year revenue forecasts because generics could cut into sales of its anti-arthritis drug, Celebrex. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com
Nigeria Ups Ebola Stakes on 1st Death

Nigeria Ups Ebola Stakes on 1st Death

Reuters - Business Video Online (July 29, 2014) Nigerian authorities have shut and quarantined a Lagos hospital where a Liberian man died of the Ebola virus, the first recorded case of the highly-infectious disease in Africa's most populous economy. David Pollard reports Video provided by Reuters
Powered by NewsLook.com
Running 5 Minutes A Day Might Add Years To Your Life

Running 5 Minutes A Day Might Add Years To Your Life

Newsy (July 29, 2014) According to a new study, just five minutes of running or jogging a day could add years to your life. Video provided by Newsy
Powered by NewsLook.com
Ebola Outbreak Poses Little Threat To U.S.: CDC

Ebola Outbreak Poses Little Threat To U.S.: CDC

Newsy (July 29, 2014) The Ebola outbreak in West Africa poses little threat to Americans, according to officials with the Centers for Disease Control and Prevention. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

More Coverage


Researchers Correct Sickle Cell Disease in Adult Mice: Protein Could Be a Target for Treating People Who Have the Blood Disorder

Oct. 13, 2011 Scientists have corrected sickle cell disease in adult laboratory mice by activating production of a special blood component normally produced before, but not after, ... read more
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins